NTLA

Company Overview — What Does Intellia Therapeutics, Inc. Do?

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Intellia Therapeutics, Inc. (NTLA) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO John M. Leonard and employs approximately 600 people, headquartered in Cambridge, Massachusetts. With a market capitalization of $1.6B, NTLA is one of the notable companies in the Healthcare sector.

Intellia Therapeutics, Inc. (NTLA) Stock Rating — Reduce (April 2026)

As of April 2026, Intellia Therapeutics, Inc. receives a Reduce rating with a composite score of 32.1/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.NTLA ranks #2,166 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Intellia Therapeutics, Inc. ranks #250 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

NTLA Stock Price and 52-Week Range

Intellia Therapeutics, Inc. (NTLA) currently trades at $13.46. The stock lost $0.38 (2.7%) in the most recent trading session. The 52-week high for NTLA is $28.25, which means the stock is currently trading -52.4% from its annual peak. The 52-week low is $5.90, putting the stock 128.1% above its annual trough. Recent trading volume was 1.2M shares, reflecting moderate market activity.

Is NTLA Overvalued or Undervalued? — Valuation Analysis

Intellia Therapeutics, Inc. (NTLA) carries a value factor score of 17/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 2.38x, versus the sector average of 2.75x. The price-to-sales ratio is 29.77x, compared to 1.66x for the average Healthcare stock.

At current multiples, Intellia Therapeutics, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Intellia Therapeutics, Inc. Profitability — ROE, Margins, and Quality Score

Intellia Therapeutics, Inc. (NTLA) earns a quality factor score of 23/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -67.4%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -53.8% versus the sector average of -33.1%.

On a margin basis, Intellia Therapeutics, Inc. reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -974.1% (sector: -66.1%). Net profit margin stands at -905.8%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 98.1% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

NTLA Debt, Balance Sheet, and Financial Health

Intellia Therapeutics, Inc. has a debt-to-equity ratio of 25.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 5.08x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $193M.

NTLA has a beta of 1.56, meaning it is more volatile than the broader market — a $10,000 investment in NTLA would be expected to move 56.5% more than the S&P 500 on any given day. The stability factor score for Intellia Therapeutics, Inc. is 22/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Intellia Therapeutics, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Intellia Therapeutics, Inc. reported revenue of $54M and earnings per share (EPS) of $-3.81. Net income for the quarter was $-453M. Gross margin was 100.0%. Operating income came in at $-487M.

In FY 2025, Intellia Therapeutics, Inc. reported revenue of $68M and earnings per share (EPS) of $-3.81. Net income for the quarter was $-413M. Revenue grew 16.9% year-over-year compared to FY 2024. Operating income came in at $-441M.

In Q3 2025, Intellia Therapeutics, Inc. reported revenue of $14M and earnings per share (EPS) of $-0.92. Net income for the quarter was $-101M. Revenue grew 51.3% year-over-year compared to Q3 2024. Operating income came in at $-111M.

In Q2 2025, Intellia Therapeutics, Inc. reported revenue of $14M and earnings per share (EPS) of $-0.98. Net income for the quarter was $-101M. Revenue grew 104.8% year-over-year compared to Q2 2024. Operating income came in at $-110M.

Over the past 8 quarters, Intellia Therapeutics, Inc. has demonstrated a growth trajectory, with revenue expanding from $7M to $54M. Investors analyzing NTLA stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

NTLA Dividend Yield and Income Analysis

Intellia Therapeutics, Inc. (NTLA) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

NTLA Momentum and Technical Analysis Profile

Intellia Therapeutics, Inc. (NTLA) has a momentum factor score of 55/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 21/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 46/100 reflects moderate short selling activity.

NTLA vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Intellia Therapeutics, Inc. (NTLA) ranks #250 out of 838 stocks based on the Blank Capital composite score. This places NTLA in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing NTLA against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full NTLA vs S&P 500 (SPY) comparison to assess how Intellia Therapeutics, Inc. stacks up against the broader market across all factor dimensions.

NTLA Next Earnings Date

No upcoming earnings date has been announced for Intellia Therapeutics, Inc. (NTLA) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy NTLA? — Investment Thesis Summary

The quantitative profile for Intellia Therapeutics, Inc. suggests caution. The quality score of 23/100 flags below-average profitability. The value score of 17/100 indicates premium valuation. High volatility (stability score 22/100) increases portfolio risk.

In summary, Intellia Therapeutics, Inc. (NTLA) earns a Reduce rating with a composite score of 32.1/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on NTLA stock.

Related Resources for NTLA Investors

Explore more research and tools: NTLA vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare NTLA head-to-head with peers: NTLA vs AZN, NTLA vs SLGL, NTLA vs VMD.